OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Results of Operations and Financial ConditionItem 2.02
Results of Operations and Financial Condition
OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Results of Operations and Financial Condition
On August 8, 2017, Orexigen Therapeutics, Inc. (“Orexigen” or the “Company”) issued a press release announcing its financial results for the three months ended June 30, 2017. A copy of this press release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
|
Item 2.02 |
Financial Statements and Exhibits |
(d) Exhibits.
|
ExhibitNo. |
Description |
|
99.1 |
Press Release, dated August 8, 2017 |
Orexigen Therapeutics, Inc. ExhibitEX-99.1 2 orex-ex991_15.htm EX-99.1 orex-ex991_15.htm Exhibit 99.1 Orexigen Therapeutics Announces Second Quarter 2017 Financial Results Contrave achieves all-time high for quarterly U.S. net sales,…To view the full exhibit click here
About OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX)
Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.
